Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Lycanbull Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825866616254480384.png) Lycanbull [@Lycanbull](/creator/twitter/Lycanbull) on x 4957 followers
Created: 2025-05-28 12:31:21 UTC

$HALO Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications


![](https://pbs.twimg.com/card_img/1926353570791575552/1aP9ElXh?format=png&name=600x314)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1927704246041854008/c:line.svg)

**Related Topics**
[$halo](/topic/$halo)
[$bmy](/topic/$bmy)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/Lycanbull/status/1927704246041854008)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Lycanbull Avatar Lycanbull @Lycanbull on x 4957 followers Created: 2025-05-28 12:31:21 UTC

$HALO Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

XXX engagements

Engagements Line Chart

Related Topics $halo $bmy stocks healthcare

Post Link

post/tweet::1927704246041854008
/post/tweet::1927704246041854008